Pertussis vaccines: Where to now?

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1497-1500

  Poolman, Jan T ^a   Hallander, Hans ^b   Halperin, Scott A ^c  

^a CRUCELL HOLLAND BV   (Netherlands)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

acellular pertussis vaccine; aP; diagnostics; pertussis; waning immunity; whole cell pertussis vaccine; wP

Indexed keywords

BACTERIUM ANTIBODY; HEMAGGLUTININ; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANTIBODY RESPONSE; BACTERIAL STRAIN; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; DRUG EFFICACY; EPIDEMIC; FIMBRIA; HEALTH CARE QUALITY; HUMAN; INCIDENCE; INFECTION CONTROL; NONHUMAN; PERTUSSIS; POLYMERASE CHAIN REACTION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG DISCOVERY; HUMANS; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; WHOOPING COUGH; WORLD HEALTH; YOUNG ADULT;

EID: 80455126029     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.147     Document Type: Review

References (32)

1. Edwards KM, Decker MD. Pertussis vaccine. In: Vaccines. Plotkin AS, Orenstein WA (Eds). Saunders, Philadelphia, PA, USA 471-528 (2004).
2. Cherry JD. Historical review of pertussis and the classical vaccine. J. Infect. Dis. 74(Suppl. 3), S259-S263 (1996). (Pubitemid 26357202)
3. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J. 22(1), 22-27 (2003). (Pubitemid 36091773)
4. de Melker HE, Conyn-van Spaendonck MA, Rümke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerging Infect. Dis. 3(2), 175-178 (1997). (Pubitemid 127431675)
5. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev. 2011(1), CD001478 (2011).
6. Pertussis surveillance in Sweden - 12 year report. October 1. 1997 until December 31. 2009. Smitttskiddsinstitutets rapportserie (2010).
7. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16(20), 1901-1906 (1998). (Pubitemid 28473933)
8. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916 (1998). (Pubitemid 28473934)
9. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(40), 385-400 (2010).
10. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361(9368), 1521-1523 (2003). (Pubitemid 36566346)
11. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J. Infect. Dis. 182(5), 1409-1416 (2000).
12. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti- PT) in Sweden before and 10 years afterthe introduction of a universal childhood pertussis vaccination program. APMIS 117(12), 912-922 (2009).
13. Edelman K, He Q, Mäkinen J et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin. Infect. Dis. 44(10), 1271-1277 (2007). (Pubitemid 46717287)
14. Zepp F, Knuf M, Habermehl P et al. Cell-mediated immunity after pertussis vaccination and after natural infection. Dev. Biol. Stand. 89, 307-314 (1997).
15. Guiso N, Njamkepo E, Vié le Sage F et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25(8), 1390-1397 (2007). (Pubitemid 46091822)
16. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(Suppl. 5), S58-S61 (2005). (Pubitemid 40676539)
17. Stenger RM, Smits M, Kuipers B et al. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine 28(40), 6637-6646 (2010).
18. van Gent M, Bart MJ, van der Heide HGJ et al. SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS ONE 6(5), e20340 (2011).
19. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev. Vaccines 8(7), 863-875 (2009).
20. Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun. Dis. Rep. CDR Rev. 2(13), R152-R154 (1992).
21. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson R-M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43(6), 2856-2865 (2005). (Pubitemid 40827964)
22. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev. Vaccines 6(1), 47-56 (2007). (Pubitemid 46232480)
23. van Loo IHM, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40(6), 1994-2001 (2002). (Pubitemid 34596374)
24. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53(Pt 5), 355-365 (2004). (Pubitemid 38586500)
25. Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 29(18), 3438-3442 (2011).
26. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccinedriven evolution. Infect. Immun. 66(2), 670-675 (1998). (Pubitemid 28074211)
27. van Amersfoorth SCM, Schouls LM, van der Heide HGJ et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol. 43(6), 2837-2843 (2005). (Pubitemid 40827962)
28. Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev. Vaccines 4(5), 757-778 (2005).
29. Visser HK. Health Council of the Netherlands advisory report 'Vaccination against pertussis' - time for a new vaccine. Ned Tijdschr Geneeskd. 148(19), 916-918 (2004). (Pubitemid 38758118)
30. Godfroid F, Denoël P, de Grave D, Schuerman L, Poolman J. Diphtheriatetanus- pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int. J. Med. Microbiol. 294(5), 269-276 (2004). (Pubitemid 39381964)
31. Storsaeter J, Wolter J. Is there a need for a new generation of vaccines against pertussis? Expert Opin. Emerg. Drugs 11(2), 195-205 (2006). (Pubitemid 43723303)
32. Feunou PF, Kammoun H, Debrie A-S, Mielcarek N, Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28(43), 7047-7053 (2010).